Review of Reported Adverse Events and Poisonings Associated with Cough and Cold Products in Young Children Joint Meeting of the Nonprescription Drugs Advisory.

Slides:

Advertisements

Similar presentations

Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.

Advertisements

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 77 Drugs for Allergic Rhinitis, Cough, and Colds.

Acute Liver Failure in the USA: Results of the US ALF Study Group William M. Lee, MD Meredith Mosle Distinguished Professor in Liver Disease University.

Over-the-Counter Cough and Cold Products for Children Under Age 6 Joshua M. Sharfstein, M.D. Commissioner of Health Baltimore, Maryland October 18, 2007.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.

Introduction The purpose of this presentation is to encourage the NDAC to: Endorse (once again) the use of a dosing schedule based on the more finely divided.

Pediatric Prehospital Seizure Management: Evidence Based Guidelines and State of Care in CO Kathleen Adelgais, MD MPH Pediatric Emergency Medicine Children’s.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.

Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.

Literature Review: Safety & Efficacy of OTC Cough & Cold Drug Products in Pediatric Patients Joint Meeting of the Nonprescription Drugs Advisory Committee.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.

Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator.

Anti-Infective Drugs Advisory Committee Meeting September 12, Andrew Mosholder, M.D., M.P.H. Medical Officer Division of Drug Risk Evaluation Office.

Acetaminophen Overdoses: A Review of Intentional and Unintentional Cases Hospital of the University of Pennsylvania Philadelphia, PA Sarah Erush, PharmD,

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

1 Regulatory History of OTC Phenylpropanolamine Hydrochloride (PPA) Robert L. Sherman Division of OTC Drug Products Center for Drug Evaluation and Research.

Over the Counter Medication :. Overview of OTC Medications (Harris Survey) > 100,000 OTC Products Few unique active ingredients > 700 are former Rx meds.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

NDAC December 14, Nonprescription Drugs Advisory Committee Meeting Silver Spring, Maryland December 14, 2007 Mary S. Robinson, MS Division of Nonprescription.

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.

Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,

1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD,

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Is It Medicine or Is it Candy? Catherine M. Tom, PharmD Assistant Professor of Pharmacy Practice Arnold & Marie Schwartz College of Pharmacy and Health.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

Locatelli F et al. Proc ASH 2013;Abstract 4378.

Update on the febrile seizure signal after influenza vaccine David Martin, MD, MPH Pharmacovigilance Branch Division of Epidemiology Office of.

Teriparatide or LY Eli Lilly & Company NDA Metabolic-Endocrine Drugs Metabolic-Endocrine Drugs Advisory Committee Advisory Committee Bethesda,

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

Over-the-Counter Cough and Cold Product Medication Errors (in children under six years of age) Joint Meeting of the Nonprescription Drugs Advisory Committee.

OTC NSAID and ASA GI Bleeding Analysis of Spontaneous Reports Nonprescription Drugs Advisory Committee Meeting Joyce P. Weaver, Pharm.D. Office of Drug.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 19, 2002.

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

Poison Center Exposure Calls Predict Mortality due to Prescription Opioid Poisoning Nabarun Dasgupta 1, J. Elise Bailey 2, Richard C. Dart 2,3, Michele.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

TM Influenza Vaccine Safety in Children: Data from VAERS John Iskander MD MPH Gina Mootrey DO MPH Penina Haber MPH Roseanne English-Bullard BS.

Allegheny County Child Death Review Allegheny County Health Department Office of Epidemiology and Biostatistics Presenter: Erin Austin Faculty Advisor:

Seizure Incidence Associated with Bupropion Dosing Errors Reported to a Local Poison Center William Eggleston, PharmD 1 and Ross W. Sullivan, MD 1,2 1.

Drugs for Allergic Rhinitis, Cough, and Colds. Allergic Rhinitis  Inflammatory disorder of the upper airway, lower airway, and eyes  Symptoms  Sneezing.

Jessica E. Bates, Pharm.D. PGY-1 Pharmacy Resident

8. Causality assessment:

Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.

Presentation transcript:

Review of Reported Adverse Events and Poisonings Associated with Cough and Cold Products in Young Children Joint Meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18, 2007 Silver Spring, Maryland Gita Akhavan-Toyserkani, Pharm.D., MBA Yoo Jung Chang, Pharm.D. Syed Rizwanuddin Ahmad, M.D., MPH Division of Drug Risk Evaluation Office of Surveillance and Epidemiology Joint Meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18, 2007 Silver Spring, Maryland Gita Akhavan-Toyserkani, Pharm.D., MBA Yoo Jung Chang, Pharm.D. Syed Rizwanuddin Ahmad, M.D., MPH Division of Drug Risk Evaluation Office of Surveillance and Epidemiology Center for Drug Evaluation and Research

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Outline Objectives Adverse Event Reporting System (AERS) database –AERS review of pediatric deaths –AERS review of serious * adverse events in children Toxic Exposure Surveillance System (TESS) database –Database of the AAPCC Overall Summary Points to Consider Objectives Adverse Event Reporting System (AERS) database –AERS review of pediatric deaths –AERS review of serious * adverse events in children Toxic Exposure Surveillance System (TESS) database –Database of the AAPCC Overall Summary Points to Consider * Serious outcomes per regulatory definition includes death, hospitalization, life-threatening, disability, congenital anomaly, requiring intervention, and other.

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, ObjectivesObjectives Present AERS cases of serious adverse events, including deaths associated with cough/cold medications in children < 6 years of age Discuss contribution of drug overdoses to serious adverse events Show most AE cases were reported in age groups where there are no dosing recommendations on the OTC product label Present AERS cases of serious adverse events, including deaths associated with cough/cold medications in children < 6 years of age Discuss contribution of drug overdoses to serious adverse events Show most AE cases were reported in age groups where there are no dosing recommendations on the OTC product label

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, ObjectivesObjectives Discuss association of single vs. multi- ingredient cough/cold products to serious adverse events Discuss association of Rx vs. OTC cough/ cold products to serious adverse events Review overdose and poisoning exposure cases in association with cough/cold products reported to the AAPCC Discuss association of single vs. multi- ingredient cough/cold products to serious adverse events Discuss association of Rx vs. OTC cough/ cold products to serious adverse events Review overdose and poisoning exposure cases in association with cough/cold products reported to the AAPCC

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Voluntary, “spontaneous” reporting Facilitated by the FDA MedWatch Program Reports stored and retrieved via Adverse Event Reporting System (AERS) database Voluntary, “spontaneous” reporting Facilitated by the FDA MedWatch Program Reports stored and retrieved via Adverse Event Reporting System (AERS) database AERS: Spontaneous AE Reporting

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Strengths Includes all U.S. marketed products Detection of events not seen in clinical trials Especially good for events with rare background rate, short latency Includes all U.S. marketed products Detection of events not seen in clinical trials Especially good for events with rare background rate, short latency

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Limitations Extensive underreporting –New reporting requirements for OTC monograph products (effective December 22, 2007) Quality of reports is variable Reporting biases Actual numerator & denominator not known Causality of drug-event association often in question Extensive underreporting –New reporting requirements for OTC monograph products (effective December 22, 2007) Quality of reports is variable Reporting biases Actual numerator & denominator not known Causality of drug-event association often in question

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Pediatric Deaths

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Pediatric Deaths (1969 – September 2006) Search Criteria AERS database: –Fatalities in children ≤ 6 years of age Includes U.S. only, single/combination, and Rx/OTC products Associated with the following ingredients: Search Criteria AERS database: –Fatalities in children ≤ 6 years of age Includes U.S. only, single/combination, and Rx/OTC products Associated with the following ingredients: Decongestants: 1.pseudoephedrine 2.phenylephrine 3.ephedrine Decongestants: 1.pseudoephedrine 2.phenylephrine 3.ephedrine Antihistamines: 1.diphenhydramine 2.brompheniramine 3.chlorpheniramine Antihistamines: 1.diphenhydramine 2.brompheniramine 3.chlorpheniramine

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Pediatric Deaths: Decongestants Number of cases: –Pseudoephedrine (46) –Phenylephrine (4) –Ephedrine (4) Majority (83%) of the decongestant cases were reported in children < 2 years of age Drug overdose 72% Rx (46%) and OTC (33%) cough/cold products were reported Majority (83%; 24/28) of the cases with a reported postmortem blood level were above the adult therapeutic level Number of cases: –Pseudoephedrine (46) –Phenylephrine (4) –Ephedrine (4) Majority (83%) of the decongestant cases were reported in children < 2 years of age Drug overdose 72% Rx (46%) and OTC (33%) cough/cold products were reported Majority (83%; 24/28) of the cases with a reported postmortem blood level were above the adult therapeutic level

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Pediatric Deaths DrugPseudoephedrine (n=46) Phenylephrine (n=4) Ephedrine (n=4) Overdose N=35: Use of multiple cough/cold preparations (7), medication error (10), accidental exposure (1), intentional overdose (2), drug interaction (1), opiate intoxication (2), unknown (12) N=1: Intentional overdose (1) N=3: Multiple drug intoxication (2), drug intoxication (1) Reported Cause of Death Drug intoxication/overdose (12), SIDS (7), apnea of prematurity (1), subarachnoid hemorrhage (1), cardiorespiratory arrest (2), head trauma (1), unknown (22) Overdose (1), SIDS (1), unknown (2) Drug intoxication (2), SIDS/ suspected drug intoxication (1), unknown (1)

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Pediatric Deaths: Antihistamines Number of cases: –diphenhydramine (33) –brompheniramine (9) –chlorpheniramine (27) Majority (59%) of the antihistamine cases were reported in children < 2 years of age Drug overdose 65% Rx (28%) and OTC (19%) cough/cold products were reported Majority (64%;18/28) of the cases with a reported postmortem blood level were above the adult therapeutic level Number of cases: –diphenhydramine (33) –brompheniramine (9) –chlorpheniramine (27) Majority (59%) of the antihistamine cases were reported in children < 2 years of age Drug overdose 65% Rx (28%) and OTC (19%) cough/cold products were reported Majority (64%;18/28) of the cases with a reported postmortem blood level were above the adult therapeutic level

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Pediatric Deaths DrugDiphenhydramine (n=33) Brompheniramine (n=9) Chlorpheniramine (n=27) Drug Overdose N=20: Intentional overdose (4), medication error (5), multi-drug intoxication (3), accidental exposure (3), unknown (5) N=5: Intentional overdose (2) use of multiple cough/cold products (1), medication error (1), accidental exposure (1) N=20: Intentional overdose (4), medication error (5), multi-drug intoxication (3), accidental exposure (3), unknown (5) Reported Cause of Death Drug intoxication/ overdose(12), SIDS (1), ARDS (1), asphyxiation (2), septic shock (1), multi-organ failure (1), acute febrile illness (1), unknown (14) Drug intoxication/ overdose (3), SIDS (1), viral pneumonia (1), apnea (1), head trauma (1), unknown (2) Drug intoxication/overdose (9), opiate intoxication (1), SIDS (1), subarachnoid hemorrhage (1), pulmonary edema (1), cardiopulmonary arrest (1), unknown (12)

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Serious* Adverse Events in Children * Serious per regulatory definition includes death, hospitalization, life-threatening, disability, congenital anomaly, requiring intervention, and other.

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children (January 1, 2002 – May 11, 2007) AERS database: –Serious adverse events in children < 6 years Includes U.S. only, single/combination, and Rx/OTC products Associated with the following ingredients: –Decongestant: pseudoephedrine –Antitussive: dextromethorphan –Antihistamines: chlorpheniramine, diphenhydramine AERS database: –Serious adverse events in children < 6 years Includes U.S. only, single/combination, and Rx/OTC products Associated with the following ingredients: –Decongestant: pseudoephedrine –Antitussive: dextromethorphan –Antihistamines: chlorpheniramine, diphenhydramine

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Demographics DrugPseudo- ephedrine (n=150) Dextro- methorphan (n=105) Chlorphen- iramine (n=63) Diphen- hydramine (n=83) Age: range median (month) 2 wks–5 yrs 18 1 mo–5 yrs 18 1 mo–5 yrs 24 3 wks–5 yrs 24 0 – < 2 yrs 2 – 5 yrs 82 (55%) 65 (43%) 57 (54%) 48 (46%) 22 (35%) 41 (65%) 39 (47%) 44 (53%) Gender: female male unspecified

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Dose and Onset DrugPseudo- ephedrine (n=150) Dextro- methorphan (n=105) Chlorphen- iramine (n=63) Diphen- hydramine (n=83) Single Dose (mg) 2.25 – 150 median: 15 (n=61) <1 – 50 median: 5 (n=61) 0.05 – 12 median: 1 (n=32) 1 – 100 median: 12.5 (n=28) Time to Onset 1 dose–> 2 wks median: 1 dose (n=89) 1 dose–> 2 wks median: 1 dose (n=55) 1 dose–10 days median: 1 dose (n=36) 1 dose– 2 wks median: 1 dose (n=29) Recommended dosage for 2-6 years of age: pseudoephedrine 15 mg q4-6 hours; dextromethorphan mg q4 hours; chlorpheniramine 1 mg q4-6 hours; diphenhydramine 6.25 mg q4-6 hours Recommended dosage for 2-6 years of age: pseudoephedrine 15 mg q4-6 hours; dextromethorphan mg q4 hours; chlorpheniramine 1 mg q4-6 hours; diphenhydramine 6.25 mg q4-6 hours

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Product Classification DrugPseudo- ephedrine (n=150) Dextro- methorphan (n=105) Chlorphen- iramine (n=63) Diphen- hydramine (n=83) Product Classification OTC Rx Unknown Product Type SI* Combo** Unknown SI*=single ingredient product, Combo**=combination/multiple ingredient product

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Serious AE: Drug Overdose DrugPseudo- ephedrine (n=150) Dextro- methorphan (n=105) Chlorphen- iramine (n=63) Diphen- hydramine (n=83) Drug Overdose74 (49%) 41 (39%) 31 (49%) 46 (55%) Manner of Overdose: Accidental exposure Intentional overdose Medication error * Undetermined * Medication errors to include prescribing errors, dispensing errors, administration errors, duplication of therapy, and wrong drug administration.

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: By System Organ Class DrugPseudo- ephedrine (n=150) Dextro- methorphan (n=105) Chlorphen- iramine (n=63) Diphen- hydramine (n=83) Cardiac Disorders Nervous System Disorders: Convulsion Depressed LOC Respiratory Disorders LOC=level of consciousness, AE=adverse events

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Overdoses vs. Non-Overdoses PSE=pseudoephedrine, CPM=chlorpheniramine, DPH=diphenhydramine, DXM=dextromethorphan, LOC=level of consciousness, AE=adverse events

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Children < 2 yrs vs. 2-5 yrs PSE=pseudoephedrine, CPM=chlorpheniramine, DPH=diphenhydramine, DXM=dextromethorphan, LOC=level of consciousness, AE=adverse events

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Hallucinations DrugPseudo- ephedrine (n=8) Dextro- methorphan (n=4) Chlorphen- iramine (n=3) Diphen- hydramine (n=9) Age < Age 2 – 5 ≤ Therapeutic Dose > Therapeutic Dose Time to Onset1 dose– 2 days (n=6) 1 dose–2 days (n=4) 1 dose–3 days (n=3) 1 dose–1 day (n=5) Type of Hallucination Visual – 3 Unknown – 5 Visual – 2 Unknown – 2 Visual – 2 Unknown – 1 Visual – 4 Auditory – 1 Unknown – 4

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Hallucinations Description of visual hallucinations: –“bubbles” –“snakes and frogs” –“big creature” –“snakes, spiders, and scorpions” –“imaginary things” –“spiders” –“bugs everywhere, balls were coming after her, and raining in her room” Description of visual hallucinations: –“bubbles” –“snakes and frogs” –“big creature” –“snakes, spiders, and scorpions” –“imaginary things” –“spiders” –“bugs everywhere, balls were coming after her, and raining in her room”

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Serious AE in Children: Postmortem Blood Levels DrugPseudo- ephedrine (n=150) Dextro- methorphan (n=105) Chlorphen- iramine (n=63) Diphen- hydramine (n=83) Death Postmortem blood levels median <0.05 – 29.9 mg/L 2.75 mg/L (n=33) 9 – 1200 mcg/L 140 mcg/L (n=16) 0.04 – 0.21 mg/L 0.07 mg/L (n=6) 0.07 – >10 mg/L 1.6 mg/L (n=14) Therapeutic blood concentrations: pseudoephedrine 1 <1 mg/L, dextromethorphan – 207 mcg/L, chlorpheniramine – 0.02 mg/L, diphenhydramine – 1 mg/L 1 Toxic Drug Concentrations. Office of the Chief Medical Examiner. Chapel Hill, NC Last revision: May 22, Gunn VL, et al. Toxicity of Over-the-Counter Cough and Cold Medications. Pediatrics. Sept 2001;108:3.

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Cardiac Case #1 2 month old, female –Infant PediaCare Decongestant and Cough Concentrated Drops, recommended by a pharmacist –Indication, PMHx and concomitant meds unknown –1 hr after a single dose of 0.4 mL (pseudoephedrine 3.75 mg and dextromethorphan 1.25 mg) –heart rate of 240 bpm and was hospitalized –AEs resolved within 7 days 2 month old, female –Infant PediaCare Decongestant and Cough Concentrated Drops, recommended by a pharmacist –Indication, PMHx and concomitant meds unknown –1 hr after a single dose of 0.4 mL (pseudoephedrine 3.75 mg and dextromethorphan 1.25 mg) –heart rate of 240 bpm and was hospitalized –AEs resolved within 7 days

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Cardiac Case #2 2 week old, male –Infant PediaCare Decongestant Concentrated Drops (pseudoephedrine mg/mL), recommended by a physician –to treat nasal congestion –no reported PMHx and no concurrent medications –immediately after 1 st dose (dose unspecified) –cardiac failure & supraventricular tachycardia –treated with digoxin and an unspecified medication –discharged after 2 weeks with events resolved 2 week old, male –Infant PediaCare Decongestant Concentrated Drops (pseudoephedrine mg/mL), recommended by a physician –to treat nasal congestion –no reported PMHx and no concurrent medications –immediately after 1 st dose (dose unspecified) –cardiac failure & supraventricular tachycardia –treated with digoxin and an unspecified medication –discharged after 2 weeks with events resolved

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Convulsion Case 5 year old, female –Triaminic Cough and Sore Throat –used for cough –1 dose (5 mL) of 15 mg of pseudoephedrine, 5 mg dextromethorphan, and 160 mg acetaminophen –seizures (lasted 10 sec) next morning –“all vitals were fine” –outcome and interventions unknown –At 3 y/o age experienced same event with the same medication –on multivitamins 5 year old, female –Triaminic Cough and Sore Throat –used for cough –1 dose (5 mL) of 15 mg of pseudoephedrine, 5 mg dextromethorphan, and 160 mg acetaminophen –seizures (lasted 10 sec) next morning –“all vitals were fine” –outcome and interventions unknown –At 3 y/o age experienced same event with the same medication –on multivitamins

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Serious AE in Children: Summary > 50% of pseudoephedrine and dextromethorphan cases occurred in children < 2 years of age > 50% of chlorpheniramine and diphenhydramine cases occurred in children 2 – 5 years of age Rx and OTC cold/cough products were reported; however, the majority were OTC (56 – 78%) > 75% pseudoephedrine, chlorpheniramine, and dextromethorphan cases involved a multi-ingredient product > 50% of pseudoephedrine and dextromethorphan cases occurred in children < 2 years of age > 50% of chlorpheniramine and diphenhydramine cases occurred in children 2 – 5 years of age Rx and OTC cold/cough products were reported; however, the majority were OTC (56 – 78%) > 75% pseudoephedrine, chlorpheniramine, and dextromethorphan cases involved a multi-ingredient product

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AERS Review of Serious AE in Children: Summary Deaths 30% Overdoses 48% Among all cases: –22% accidental exposures –6% intentional overdoses –9% medication errors –11% indeterminable Serious adverse events related to the cardiac, nervous, and respiratory systems have been reported both in the setting of an overdose and outside of an overdose –Convulsions: more common outside of an overdose and appear more in children 2 – 5 years of age –Cardiac & respiratory events: more common in the setting of an overdose Deaths 30% Overdoses 48% Among all cases: –22% accidental exposures –6% intentional overdoses –9% medication errors –11% indeterminable Serious adverse events related to the cardiac, nervous, and respiratory systems have been reported both in the setting of an overdose and outside of an overdose –Convulsions: more common outside of an overdose and appear more in children 2 – 5 years of age –Cardiac & respiratory events: more common in the setting of an overdose

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, TESS Review

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, TESS Review TESS - Toxic Exposure Surveillance System is the poisoning surveillance database of the AAPCC –Reviewed reports from –Cases that listed cough/cold preparations or diphenhydramine –Caveat: Underreporting to TESS may be extensive TESS - Toxic Exposure Surveillance System is the poisoning surveillance database of the AAPCC –Reviewed reports from –Cases that listed cough/cold preparations or diphenhydramine –Caveat: Underreporting to TESS may be extensive

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, TESS Review – Cough/Cold In children < 6 yrs –Total # cases increased slightly from 59,949 in 2001 to 70,398 in 2005 –Overall % of cases involving children < 6 yrs remained constant at about % in the 5-yr review period For all ages, majority of these cases resulted from unintentional exposures –24% were treated in a health care facility In children < 6 yrs –Total # cases increased slightly from 59,949 in 2001 to 70,398 in 2005 –Overall % of cases involving children < 6 yrs remained constant at about % in the 5-yr review period For all ages, majority of these cases resulted from unintentional exposures –24% were treated in a health care facility

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, TESS Review - Diphenhydramine In children < 6 yrs –Total # of cases increased very slightly from 13,044 in 2001 to 13,445 in 2005 –Overall % of cases involving children < 6 yrs remained constant at about 43-46% For all ages, 45-75% of diphenhydramine cases resulted from unintentional exposure –42% required treatment in a health care facility In children < 6 yrs –Total # of cases increased very slightly from 13,044 in 2001 to 13,445 in 2005 –Overall % of cases involving children < 6 yrs remained constant at about 43-46% For all ages, 45-75% of diphenhydramine cases resulted from unintentional exposure –42% required treatment in a health care facility

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, TESS Review - Fatalities In children < 6 yrs, 14 fatalities were reported in association with cough/cold and diphenhydramine products Age range 2m-5yrs Majority of deaths (N=8) occurred in children 12m or younger Product –3 fatalities were noted in association with the use of single ingredient cough/cold or diphenhydramine products –11 fatalities noted with combination products or use of multiple products In children < 6 yrs, 14 fatalities were reported in association with cough/cold and diphenhydramine products Age range 2m-5yrs Majority of deaths (N=8) occurred in children 12m or younger Product –3 fatalities were noted in association with the use of single ingredient cough/cold or diphenhydramine products –11 fatalities noted with combination products or use of multiple products

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, TESS Review - Summary Data from poison control centers suggest substantial number of overdose and poisonings in association with cough/cold and diphenhydramine products –Both OTC and Rx products involved Children < 6 years old make up 40% to 60% of all poisoning cases in association with cough/cold and diphenhydramine products Data from poison control centers suggest substantial number of overdose and poisonings in association with cough/cold and diphenhydramine products –Both OTC and Rx products involved Children < 6 years old make up 40% to 60% of all poisoning cases in association with cough/cold and diphenhydramine products

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Overall Summary Use of OTC and Rx cough/cold medications in children < 6 years of age have been associated with serious adverse events, including death Drug overdoses commonly contributed to serious adverse events and deaths Manner of overdose was identified as: –accidental exposure, intentional overdose, and medication errors Use of OTC and Rx cough/cold medications in children < 6 years of age have been associated with serious adverse events, including death Drug overdoses commonly contributed to serious adverse events and deaths Manner of overdose was identified as: –accidental exposure, intentional overdose, and medication errors

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Overall Summary Most occurred in age groups where there are no dosing recommendations on the OTC product label Most involved multi-ingredient cough/cold products Data from poison control centers suggest substantial number of overdose and poisonings cases reported with cough/cold and diphenhydramine products Most occurred in age groups where there are no dosing recommendations on the OTC product label Most involved multi-ingredient cough/cold products Data from poison control centers suggest substantial number of overdose and poisonings cases reported with cough/cold and diphenhydramine products

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, Points to Consider An educational campaign directed towards healthcare providers and parents about the use of cough/cold products The labeling of cough/cold products should include prominent language to describe the risk of overdose in children Label should indicate that cough/cold products are not recommend in children under 2 years of age Consider having only single ingredient cough/cold products for pediatric formulations An educational campaign directed towards healthcare providers and parents about the use of cough/cold products The labeling of cough/cold products should include prominent language to describe the risk of overdose in children Label should indicate that cough/cold products are not recommend in children under 2 years of age Consider having only single ingredient cough/cold products for pediatric formulations

Joint meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee October 18 & 19, AcknowledgementsAcknowledgements Mark Avigan, M.D., C.M. Allen Brinker, M.D., M.S. Gerald Dal Pan, M.D., M.H.S Rosemary Johann-Liang, M.D. Lauren Lee, Pharm.D. Ann McMahon, M.D., M.S. Ellis Unger, M.D. Mark Avigan, M.D., C.M. Allen Brinker, M.D., M.S. Gerald Dal Pan, M.D., M.H.S Rosemary Johann-Liang, M.D. Lauren Lee, Pharm.D. Ann McMahon, M.D., M.S. Ellis Unger, M.D.